Author | Axel Grothey, MD


Adjuvant Therapy After Resection of Metastatic Colorectal Cancer: Clear Proof of Principle in This Setting

January 15, 2016

There is clear proof of principle for adjuvant therapy in patients at high risk for tumor recurrence, such as those with resected metastatic colorectal cancer. For that reason, this strategy has been largely adopted, especially using 5-FU– and oxaliplatin-based regimens, thereby mirroring the approach in resected stage III colon cancer.

Maintenance Therapy in the Treatment of Metastatic Colorectal Cancer

July 01, 2015

Ahead of the ESMO World Congress on Gastrointestinal Cancer, we are discussing the use of maintenance therapy in metastatic colorectal cancer with Axel Grothey, MD.

Circling Back: The Effects of Emerging Molecular Understanding on Treatment Decisions in Colorectal Cancer

May 01, 2014

Points made in commentaries on “Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions” are addressed by authors Hubbard and Grothey.

Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions

February 15, 2014

In this review we discuss the current treatment options in metastatic colon cancer, with a special focus on biologic agents and how molecular understanding guides treatment decisions.